Director, HEOR & RWE, Europe

Revolution Medicines is a global, commercial-state oncology company dedicated to discovering, developing and delivering innovative medicines for patients with RAS-addicted cancers. Leveraging its differentiated RAS(ON) tri-complex inhibitor platform, the company is advancing a broad, integrated portfolio of oral RAS(ON) inhibitors designed to directly target the active, cancer-driving state of RAS. Founded on rigorous scientific inquiry and a willingness to challenge long-held assumptions, Revolution Medicines is committed to changing the trajectory of disease for patients with RAS-addicted cancers worldwide.

Our people are united by a shared way of working: follow the science, challenge assumptions, act with urgency and hold ourselves to a high standard of rigor—all in service of patients.

The Director, HEOR & RWE, Europe will lead the European HEOR and RWE strategy and execution for assigned assets, disease areas, and/or evidence-generation work streams. The Director, HEOR & RWE, Europe will identify European evidence requirements and priorities and will work with European Medical Affairs, Global HEOR & RWE, Market Access, Clinical Development, and local affiliates to ensure that plans address regional and country needs.

The role will oversee HEOR/RWE evidence generation driving differentiated value demonstration across European markets and the region as a whole. Reporting to the Executive Director, HEOR & RWE, Europe and as a key member of European matrix team, the Director HEOR & RWE will establish priorities, provide expert HEOR/RWE guidance, resolve trade-offs, and ensure delivery of agreed strategic and tactical outcomes.

This is an exceptional opportunity to shape European evidence strategy and deliver decision-relevant evidence that advances patient access and care in oncology.

• European HEOR & RWE Strategy:
  Lead, own, and evolve the European HEOR and RWE strategy for assigned assets, disease areas, and/ or evidence-generation work streams across the product lifecycle. Set evidence priorities and success measures to support the medical strategy, value demonstration, pricing and reimbursement, and local HTA submissions.
• Integrated Evidence Planning: assess, prioritisise, and articulate the European evidence needs and ensure agreed plans address critical evidence gaps and regional and local requirements, with clear deliverables, accountabilities, timelines, and decision points.
• Evidence Generation & Analysis:
  Direct and be accountable for the design, execution, scientific quality, and delivery of health economic models (cost-effectiveness, budget impact), real-world evidence, burden-of-disease assessments, patient-centred outcomes research, and other evidence packages supporting regulatory filings, JCA and HTA submissions, reimbursement decisions, and payer engagement.
• Cross-Functional Leadership:
  Partner with Medical Affairs, Market Access, Commercial, Regulatory, Clinical Development, Global HEOR, and local affiliates to integrate payer and evidence requirements into development, launch, and lifecycle plans; resolve priorities and trade-offs; and drive timely execution.
• External Engagement:
  Serve as an European HEOR/RWE representative for Revolution Medicines in scientific, payer, and HTA forums. Drive strategic engagement with key opinion leaders, academic collaborators, HTA bodies, payers, data partners, and other external stakeholders to inform evidence plans and strengthen value demonstration.
• Vendor and Programme Accountability:
  Select, direct, and hold external consultants, research partners, and vendors accountable for scope, methodology, scientific quality, budget, timelines, risk management, and final outputs. Ensure deliverables are…